On February 27, 2026, HHS Secretary RFK Jr. announced 14 peptides will move from FDA Category 2 back to Category 1. Complete guide to which compounds are affected, what changes, and what stays the same.
The Announcement That Changed Everything On February 27, 2026, while appearing on Episode #2461 of the Joe Rogan Experience, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides placed on the FDA's Category 2 restricted list in 2023 will be moved back to Category 1 — restoring eligibility for legal compounding by licensed pharmacies under physician prescription. This is the most significant regulatory shift in US peptide therapy access in the past decade. For patients who had been forced toward unregulated gray-market sources, and for the physicians who had lost the ability to prescribe these compounds through legitimate channels, the announcement represents a meaningful restoration of access. But the details matter. Here is exactly what changed, what hasn't changed yet, and what it means for you.
In late 2023, the FDA moved 19 widely used peptides to its Category 2 bulk drug substances list — a designation indicating the agency believed these compounds presented "significant safety risks" that precluded their use in compounding.
The practical effect: licensed 503A and 503B compounding pharmacies could no longer legally prepare these peptides for patients. Physicians who had been prescribing compounds like BPC-157, TB-500, and Thymosin Alpha-1 through legitimate pharmaceutical channels lost access virtually overnight.
The FDA's stated rationale centered on immunogenicity concerns, manufacturing impurity risks, and the absence of large-scale human clinical trials. Critics — including many practicing physicians and compounding pharmacy groups — argued the agency had overstepped its authority and applied a standard (absence of efficacy data) that was never the legal basis for Category 2 placement.
Kennedy's announcement contained two key claims. First, that approximately 14 of the 19 restricted peptides would be moved back to Category 1. Second, that the original restrictions had been applied without the specific safety signal required by law — they were based on lack of efficacy data, not evidence of actual harm. "We created the gray market," Kennedy acknowledged, noting that the ban had driven patients toward unregulated online vendors with zero pharmaceutical oversight.
Based on regulatory analysis from compounding pharmacy groups and industry experts, the peptides most widely cited as expected to return to legal compounding status include:
Healing and Recovery
Growth Hormone Axis
Immune Support
Longevity and Anti-Aging
Note: The FDA has not published a formal updated list as of this writing. The above represents expert prediction based on the announcement, not official confirmation.
Category 1 status means a compound is eligible for use by licensed 503A compounding pharmacies (individual prescriptions) while under FDA evaluation. It does NOT mean FDA approval.
Critical distinctions:
If you have been accessing peptides through gray-market research chemical vendors due to the lack of legitimate compounding access, the reclassification creates a path to pharmaceutical-grade product through a physician.
Pharmaceutical-grade compounded peptides offer: independent third-party purity testing, accurate concentration (independent testing of research chemicals consistently shows ±40-300% concentration variance vs ±10% for pharmacy-grade product), sterile preparation under controlled conditions, and documented lot traceability.
The reclassification announcement does not change the following: the FDA has not yet published a formal updated rule; until it does, the legal status of these compounds for compounding technically remains unchanged. Physicians and pharmacies are monitoring for the formal publication before modifying their protocols.
Additionally, PT-141 (Bremelanotide), which has an FDA-approved form (Vyleesi), and several other compounds are not expected to be among the 14 reclassified.
Whether you are currently running peptides through existing channels or planning to start once pharmacy access normalizes, tracking your biomarkers is the most important thing you can do to know whether your protocol is working.
MyProtocolStack tracks 40+ biomarkers with optimal ranges, integrates StackAI blood work analysis, and logs your dose history alongside your lab draws — so you can see exactly how your protocol is moving your numbers. Enter your labs from Quest, LabCorp, or Function Health and run StackAI analysis to get personalized insights based on your actual panel.
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers — not generic charts.
Start Free →